

- **Name:** Hidetoshi Hayashi
 - **Current Position & Affiliation:** Associate Professor of the Medical Oncology at Kindai University
 - **Country:** Japan
-
- **Educational Background:**
 - ◆ M.D., Osaka University, Faculty of Medicine, March 2003
 - ◆ Ph.D. in Medical Oncology, Kindai University, Faculty of Medicine, February 2012
 - **Professional Experience:**
 - ◆ APR 2022-present: Special Associate Professor
 - ◆ APR 2020-March 2022: Senior Lecturer, Department of Medical oncology, Kindai University, Faculty of Medicine, Osaka-sayama
 - ◆ April 2015-Sep 2015: Junior Lecturer
 - ◆ April 2013-March 2015: Assistant professor, Department of Medical Oncology, Kishiwada City Hospital
 - ◆ April 2009-March 2013: Manager of Department of Medical Oncology, Department of Medical oncology, Kindai University, Faculty of Medicine, Osaka-sayama
 - ◆ Assistant professor: April 2011-March 2013, Department of genome biology, Kindai University, Faculty of Medicine, Osaka-sayama
 - ◆ April 2006-March 2009: Research Scientist, Department of Respiratory medicine, Kurashiki Central Hospital, Okayama
 - ◆ March 2006- May 2003: Fellow, Department of General medicine, Sumitomo Hospital, Osaka
 - **Professional Organizations:**
 - ◆ Program committee, Japanese Board of Cancer Therapy (2017-)
 - ◆ Program committee, Annual meeting of Japanese Society of Medical Oncology (2017-)
 - ◆ Board certification committee, Japanese Society of Medical Oncology (2019-)
 - ◆ Membership committee, International Association for the Study of Lung Cancer (2020-)
 - ◆ COVID-19 surveillance committee, International Association for the Study of Lung Cancer (2020-)
 - ◆ Deputy editor, International Journal of Clinical Oncology (2020-)
 - ◆ Program chair, World Lung Cancer Conference 2021
 - **Main Scientific Publications:**

Publications-Journals (List in order shown below. ※: corresponding author)

 - ◆ Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H※. Ann Oncol. 2021 Nov 26:S0923-7534(21)04824-9. doi:

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

10.1016/j.annonc.2021.11.009. Online ahead of print.

- ◆ Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, Kim DW, Koczywas M, Gold KA, Steuer CE, Murakami H, Yang JC, Kim SW, Vigliotti M, Shi R, Qi Z, Qiu Y, Zhao L, Sternberg D, Yu C, Yu HA. *Cancer Discovery*. 2022 Jan;12(1):74-89. doi: 10.1158/2159-8290.CD-21-0715. Epub 2021 Sep 21.
- ◆ A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Hayashi H✉, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K. *Clin Cancer Res*. 2021 Dec 17;clincanres.3194.2021. doi: 10.1158/1078-0432.CCR-21-3194. Online ahead of print.
- ◆ MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer. Cho BC, Felip E, Hayashi H, Thomas M, Lu S, Besse B, Sun T, Martinez M, Sethi SN, Shreeve SM, Spira AI. *Future Oncol*. 2021 Dec 16. doi: 10.2217/fo-2021-0923. Online ahead of print.
- ◆ Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). Haratake N, Hayashi H✉, Shimokawa M, Nakano Y, Azuma K, Oki M, Ota K, Yoshioka H, Sakamoto T, Yamamoto N, Nakagawa K, Seto T. *Clin Lung Cancer*. 2021 Oct 24:S1525-7304(21)00270-9. doi: 10.1016/j.clcc.2021.10.007. Online ahead of print.
- ◆ Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Hayashi H✉, Nadal E, Gray JE, Ardizzoni A, Caria N, Puri T, Groe C. *Clin Lung Cancer*. 2021 Oct 25:S1525-7304(21)00273-4. doi: 10.1016/j.clcc.2021.10.009. Online ahead of print.
- ◆ Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. Kato R, Haratani K, Hayashi H✉, Sakai K, Sakai H, Kawakami H, Tanaka K, Takeda M, Yonesaka K, Nishio K, Nakagawa K. *Br J Cancer*. 2020 Dec 10. doi: 10.1038/s41416-020-01201
- ◆ Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. Hayashi H✉, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y, Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K. *JAMA Oncology*. 2020 Oct 15:e204643.
- ◆ Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer K Isomoto, K Haratani, H Hayashi✉, S Shimizu, S Tomida, T Niwa, T Yokoyama, Y Fukuda, Y Chiba, R Kato, J Tanizaki, K Tanaka, M Takeda, T Ogura, T Ishida, A Ito, K Nakagawa *Clinical Cancer Research*.. 2020 Apr 15;26(8):2037-2046

- ◆ Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L). Kato R, Hayashi H※, Chiba Y, Miyawaki E, Shimizu J, Ozaki T, Fujimoto D, Toyozawa R, Nakamura A, Kozuki T, Tanaka K, Teraoka S, Usui K, Nishino K, Hataji O, Ota K, Ebi N, Saeki S, Akazawa Y, Okuno M, Yamamoto N, Nakagawa K. *Journal for Immunotherapy of Cancer*. 2020 Feb;8(1). pii: e000350. doi: 10.1136/jitc-2019-000350.
- ◆ Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, Awad MM, Shapiro GI, Satouchi M, Hida T, Hayashi H, Murphy DA, Wang SC, Li S, Usari T, Wilner KD, Paik PK. *Nature Medicine*. 2020 Jan;26(1):47-51
- ◆ Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K. *J Clin Oncol*. 2019 Mar 1;37(7):570-579. doi: 10.1200/JCO.18.00771
- ◆ Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. Tanizaki J, Haratani K, ※Hayashi H, Chiba Y, Nakamura Y, Yonesaka K, Kudo K, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Ito A, Nakagawa K. *J Thorac Oncol*. 2018 Jan;13(1):97-105
- ◆ Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. Haratani K, ※Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. *JAMA Oncology*. 2018 Mar 1;4(3):374-378.
- ◆ Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment. Haratani K, ※Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K. *Ann Oncol*. 2017 Jul 1;28(7):1532-1539
- ◆ The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. Hayashi H, Arai T, Togashi Y, Kato H, Fujita Y, De Velasco MA, Kimura H, Matsumoto K, Tanaka K, Okamoto I, Ito A, Yamada Y, Nakagawa K, Nishio K. *Oncogene*. 2015 Jan 8;34(2):199-208